Missed us at AACR 18?

Download our 13 scientific posters covering a wide variety of preclinical oncology and immuno-oncology platforms including NGS and transcriptomic PDX analysis, novel murine homograft models, as well as PBMC and humanized drug target models for immunotherapy assessment.

WEBINAR: Exploring Translational Capabilities of PDX Models across In Vivo, In Vitro, and Ex Vivo Applications

April 25, 10am EST / April 26, 2pm EST

Presented by Dr John MacDougall, this webinar introduces the integrated use of patient-derived xenograft (PDX) models across preclinical research for more translational studies. Learn more on the importance of using highly translational preclinical cancer models, leveraging the benefits and limitations of in vitro, ex vivo, and in vivo PDX study types, and how this variety of platforms can be used for immuno-oncology studies.

ON DEMAND WEBINAR: In Vitro and Ex Vivo Assays to Accelerate Immuno-Oncology Drug Discovery

Presented by Dr Toni Jun, this webinar introduces a one stop, integrated in vitro/ex vivo I/O assay plaform designed to effciently progress immunotherapy drug development. Learn how to monitor and assess TIL populations and functions, explore the microbiome's role in immunotherapy, and understand a wide range of functional characteristics across the I/O field including tumor microenvironment regulation.

ON-DEMAND WEBINAR: Interrogating Syngeneic Models in Large Scale, How to Use Immunoprofiling Data to Improve your Studies

Presented by Dr Henry Li, this webinar explores the detailed data analysis behind the industry's first large-scale, staggered, syngeneic screening platform for immunotherapy development. Learn how this platform can improve efficiency and reproducibility while reducing cost, how comprehensive immunophenotyping and profiling data is used to address key study design questions, and how RNAseq and FACS/IHC analysis are used for biomarker discovery.

WHITE PAPER: Immuno-Oncology - 3 Strategies for Applying Humanized Models

Enhance your humanized mouse immuno-oncology studies through a deeper understanding of model immunological features and optimized uses. Learn more about immune system humanization strategies, and how these result in different models with contrasting features and limitations, then explore model applications through cancer pharmacology case studies.

Get Your Free Poster

Learn more about the world's largest patient-derived xenograft (PDX) collection. Download or request a poster today.

Watch Henry Li present EORTC 17 Short Talk

Hear Dr Henry Li, Vice President of Biomarker and Diagnostic Technology present our AACR-NCI-EORTC 2017 selected Short Talk titled 'Transcriptomic analysis of patient-derived xenografts reveals heterogeneity in human and mouse stroma/immune compartments'

ON DEMAND WEBINAR: Clinically Relevant Cell-Based Solutions for Target Identification

Learn how to leverage CrownBio's integrated Oncology Portfolio to advance your Target Identification studies. Watch our webinar presented by Michelle Mack.

NEW WHITE PAPER: The Ultimate Guide to Mouse Clinical Trials

Transform your preclinical oncology drug development, with mouse clinical trials using patient-derived xenograft (PDX) models. Learn how the different types of MCT are executed, which is the best fit for your specific drug discovery program, and how they provide the perfect framework for biomarker discovery.

ON DEMAND WEBINAR: How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology

Presented by Dr. Keefe Chng and Dr Judith Gorski this webinar will help guide you through a study design process that will enable the greatest opportunity to generate robust, high-quality data, that gives maximum confidence to select new drug candidates and regulatory submissions.

NEW WHITE PAPER: Translational Platforms to Model Pre-Diabetes, Diabetes, and Diabetic Complications

This White Paper explores a unique platform of highly translational models recapitulating multiple aspects of disease progression as seen in humans, for preclinical efficacy studies.

Clarity with
Crown

Recognize your next clinical candidate when you see it.

Our Translational Platforms enable our clients to identify the right patients for the right treatment. Having models which more accurately mimic human disease and population dynamics are key to successfully translating promising compounds into successful clinical candidates, whether treating Oncology or Diabetes related diseases.

Magnify your
insights

Understand the mechanisms of disease.

Our scientific acumen and experience will give you a deeper understanding of not just the pharmacological profile of your compound, but more importantly, a clear understanding of which compounds to progress into the clinic. Take a look at our publications to get a deeper understanding of the depth of our scientific expertise.

Begin with the
end insight

Connecting science to patients.

We help our clients solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease by answering some of the most challenging questions about human biology.

CVMD

Models of Obesity

obesity-img.jpg

CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.

Learn More

Oncology

Oncology Databases

databases-img.jpg

Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.

Learn More

CVMD

Diabetes Models

oncoexpress-img.jpg

Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacy studies of antidiabetic agents.

Learn More

Latest from our Blog

April 20, 2018

Preclinical Assessment of Osimertinib for NSCLC with EGFR Exon 20 Insertions

NSCLC patients with EGFR exon 20 insertions lack treatment options, partly due to a lack of patient genotype-relevant preclinical models for assessing novel agents. A new publication details the preclinical evaluation of osimertinib for this EGFR mutation type, using a series of CRISPR-Cas9 engineered cell lines and patient-derived...

Read More

April 20, 2018

Preclinical Assessment of Osimertinib for NSCLC with EGFR Exon 20 Insertions

NSCLC patients with EGFR exon 20 insertions lack treatment options, partly due to a lack of...

Read More

April 13, 2018

The Establishment and Characterization of PDX Models

Patient-derived xenograft models (PDX) support more predictive, clinically-representative in vivo

Read More

April 5, 2018

The Limits of In Vitro and Ex Vivo Immuno-Oncology Assays

Studying the immune system in vivo can be challenging, and in vitro and ex vivo assays are often...

Read More

March 22, 2018

Are There Are Five Types of Diabetes?

New research suggests that there are five types of diabetes, rather than simply Type 1 or Type...

Read More

March 19, 2018

Targeting Myeloid Derived Suppressor Cells in Immuno-Oncology

Immune checkpoint inhibitors (ICIs) have dramatically changed the therapeutic approach to...

Read More

Upcoming Events


April 9 - 11, 2018

11th Diabetes Summit

Boston, MA

Preview our Oral Presentation Topic
www.gtcbio.com/diabetes/


April 14 - 18, 2018

AACR Annual Meeting 2018

Chicago, Illinois - Booth #3012

Preview our Poster Topics
www.aacr.org


April 23 - 25, 2018

2nd Annual NASH Summit 2018

Boston, MA

Preview our Poster Topic
www.nash-summit.com


May 24 - 25, 2018

3rd Annual Advances in Immuno-Oncology Congress

London, UK

Preview our Poster Topic
www.immunooncology-congress.com


April 25 - 26, 2018

Webinar: Exploring Translational Capabilities of PDX Models across In Vivo, In Vitro and Ex Vivo Applications

Register Now


June 21 - 22, 2018

Next Gen Immuno-Oncology Congress

Philadelphia, PA

www.mnmconferences.com


June 22 - 26, 2018

American Diabetes Association 78th Scientific Sessions

Orlando, FL - Booth #1615

Preview our Poster Topics
www.professional.diabetes.org